Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Obesity drug AOD-9604 begins new phase IIb study

Oct. 20, 2005

Insmed submits response to iPlex approvable letter

Oct. 20, 2005

New title added to the Drug R&D Backgrounders topic list --Osteogenesis Imperfecta

Oct. 19, 2005

Kissei seeks Japanese approval for Glufast with alpha-glucosidase inhibitor

Oct. 19, 2005

Nastech begins development of intranasal rapid-acting insulin

Oct. 19, 2005

Pioglitazone improves cardiovascular outcome in patients with type 2 diabetes

Oct. 18, 2005

New data on the metabolic effects of orexin A

Oct. 18, 2005

Oral insulin prevents postprandial glucose excursions in patients with type 1 diabetes

Oct. 18, 2005

Exubera recommended for approval in Europe

Oct. 17, 2005

Enrollment completed in ORIENT studies of olmesartan in diabetic nephropathy

Oct. 17, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 20, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...
Regeneron’s fianlimab lags in melanoma, does $2.3B deal with Parabilis
BioWorld
Regeneron Pharmaceuticals Inc. stuck with the tradition of releasing bad news on Friday afternoon and good news on Monday morning with a pair of announcements...